Skonsultuj się
CMC readiness is often discussed in terms of a technically complete Module 3. For an approaching marketing application, that definition is too narrow. The underlying manufacturing processes, controls, facilities and supporting evidence also need to be ready for Regulatory review.
FDA’s FY2025 Report on the State of Pharmaceutical Quality, released in 2026, provides fresh evidence of the importance of the connection.
A data point from FDA’s quality review
FDA analysed nearly 10,000 original applications and supplements that required facility assessments, received during fiscal years 2024 and 2025. As of May 2026, 28% of those submissions had received a Complete Response Letter (CRL). 43% of those CRLs, equivalent to 12% of all submissions in the analysed group, were associated with facility withhold.
The scope of the finding matters. This was a defined group of CDER-related applications and supplements that required facility assessment. It is not a general estimate for every NDA, ANDA, or BLA, and it does not show that every CRL was caused by CMC deficiencies.
FDA also reported that more than half of facility withholds in this analysis involved facilities with pre-existing Official Action Indicated (OAI) or potential OAI status. It highlighted inadequate investigations, insufficiently documented or followed quality-control responsibilities, and deficiencies in microbiological contamination control among common observations linked to facility withholds .
What this changes for the pre-filing discussion
The discussion should include three connected readiness layers.
Scientific and technical package. Review manufacturing process descriptions, control strategy, analytical methods, specifications, impurity assessments, stability support and comparability or validation evidence where applicable. The specific data needed will depend on product and application type.
Dossier consistency. Confirm that quality summaries and Module 3 are aligned with the source data and that any unresolved issues are tracked. The ICH M4Q(R2) revision is also drawing attention to more effective organisation and lifecycle use of quality information. As of October 2026, the revised guidance remains at Step 2b draft stage, so it should inform forward planning rather than be presented as a current mandatory format [C2].
Manufacturing and inspection readiness. Include facility status, quality-system observations, remediation commitments and inspection preparedness in the filing governance process. These are operational dependencies, not details to discover after publishing begins.
A practical readiness discussion across functions
Before committing to a target filing date, the submission lead can convene CMC, Quality, Manufacturing and Regulatory Affairs around a shared set of questions: What remains open in the control strategy? Which quality-related justifications still need final evidence? Have all relevant facilities been assessed for inspection or compliance risks? Can the team retrieve information promptly if FDA seeks clarification?
ICH Q9(R1) provides established principles for quality risk management and can help inform a structured approach to identifying and assessing pharmaceutical quality risks .
Planning for review is part of preparing to file
A CRL states that the FDA cannot approve an application in its current form and identifies deficiencies that require attention. The agency can raise questions across safety, efficacy, quality and other areas. Preparing a response requires investigation, evidence, clear scientific rationale and controlled revision of the relevant submission content. Sponsors benefit from assigning decision rights and supporting data owners before those questions arrive. Facility and CMC readiness also deserve attention throughout the review cycle, rather than only at submission lock.
A stronger filing plan connects CMC Regulatory writing, quality documentation, facility considerations, eCTD preparation and Health Authority response support. We can help sponsors assess dossier gaps, prepare CMC sections and coordinate Regulatory responses, alongside the relevant client functions and manufacturing experts.
Preparing an NDA, ANDA or BLA? Speak with our CMC Regulatory specialist about submission readiness
